title: Effect of simvastatin on bone markers in osteopenic women: a placebo-controlled, dose-ranging trial [ISRCTN85429598].
abstract: BACKGROUND
  Hydroxymethylglutaryl coenzyme A reductase inhibitors increase new bone formation in vitro and in rodents. Results of epidemiologic analyses evaluating the association between use of these cholesterol-lowering drugs, bone mineral density and fracture have been mixed.
  
  
  METHODS
  Women (n = 24) with osteopenia, assessed by broad band ultrasound attenuation, were randomized to simvastatin 20 mg, 40 mg or identical-appearing placebo for 12 weeks. Fasting lipid profiles and biochemical markers of bone formation (bone-specific alkaline phosphatase) and resorption (N-telopeptides and C-terminal propeptide of type 1 collagen) were measured at baseline, 6 and 12 weeks.
  
  
  RESULTS
  Plasma low density lipoprotein-cholesterol concentration fell 7%, 39% (p < 0.01 vs baseline) and 47% (p < 0.01 vs baseline) after 12 weeks of treatment with placebo, simvastatin 20 mg and 40 mg, respectively. At baseline, bone marker concentrations were similar in the three treatment groups. At 6 and 12 weeks, bone marker concentrations were not different from baseline, and no significant differences in bone marker concentrations were observed between treatment groups at either 6 or 12 weeks.
  
  
  CONCLUSIONS
  Among osteopenic women, treatment with simvastatin for 12 weeks did not affect markers of bone formation or resorption.
authors.affiliation: Department of Medicine, George Washington University, Washington, DC, USA. domjah@gwumc.edu
authors.forename: Judith
authors.initials: J
authors.lastname: Hsia
authors.forename: Megan
authors.initials: M
authors.lastname: Morse
authors.forename: Virginia
authors.initials: V
authors.lastname: Levin